Posted by Michael Wonder on 12 Oct 2017
Institute for Clinical and Economic Review to evaluate cystic fibrosis treatments in upcoming report
12 October 2017 - Report expected to review tezacaftor, lumacaftor, and ivacaftor (Vertex Pharmaceuticals); Open Input accepted until 27 October.
The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of treatments for cystic fibrosis. The report is tentatively expected to include tezacaftor (Vertex Pharmaceuticals) used in combination with ivacaftor (Kalydeco, Vertex Pharmaceuticals), a combination therapy currently under review by the FDA, with an approval decision expected in February of 2018. The report is also expected to review combination therapy lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), approved in 2015.
The scope of ICER's review is subject to change based on feedback received from stakeholders, including clinical experts and patients.
